{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0+mg+placebo&page=2",
    "query": {
      "intervention": "0 mg placebo",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 875,
    "total_pages": 88,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0+mg+placebo&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0+mg+placebo&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T15:24:39.893Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03787095",
      "title": "Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cemiplimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 5,
      "start_date": "2019-08-13",
      "completion_date": "2020-08-18",
      "has_results": true,
      "last_update_posted_date": "2022-03-02",
      "last_synced_at": "2026-10-02T15:24:39.893Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • San Diego, California • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03787095"
    },
    {
      "nct_id": "NCT02647866",
      "title": "Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis",
        "Digestive System Diseases",
        "Colitis, Ulcerative",
        "Colitis",
        "Gastrointestinal Diseases",
        "Inflammatory Bowel Diseases",
        "Intestinal Diseases",
        "Colonic Diseases",
        "Autoimmune Disease",
        "Abdominal Pain"
      ],
      "interventions": [
        {
          "name": "KHK4083",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyowa Kirin, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2016-06",
      "completion_date": "2018-10",
      "has_results": true,
      "last_update_posted_date": "2024-04-26",
      "last_synced_at": "2026-10-02T15:24:39.893Z",
      "location_count": 1,
      "location_summary": "Greenville, South Carolina",
      "locations": [
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02647866"
    },
    {
      "nct_id": "NCT00035529",
      "title": "A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "BMS 188667 (Abatacept)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": null,
      "start_date": "2001-11",
      "completion_date": "2003-12",
      "has_results": false,
      "last_update_posted_date": "2010-12-06",
      "last_synced_at": "2026-10-02T15:24:39.893Z",
      "location_count": 10,
      "location_summary": "New Haven, Connecticut • Louisville, Kentucky • Worcester, Massachusetts + 7 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00035529"
    },
    {
      "nct_id": "NCT02296541",
      "title": "Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DNA Nat-B env",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DNA CON-S env",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DNA Mosaic env",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-CMDR",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for DNA Nat-B env",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for DNA CON-S env",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for DNA Mosaic env",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for MVA-CMDR",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 105,
      "start_date": "2014-12",
      "completion_date": "2020-07-06",
      "has_results": false,
      "last_update_posted_date": "2023-04-24",
      "last_synced_at": "2026-10-02T15:24:39.893Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02296541"
    },
    {
      "nct_id": "NCT00890175",
      "title": "Staccato Loxapine Pulmonary Safety in Patients With Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Inhaled loxapine @ 0 & 10 h",
          "type": "DRUG"
        },
        {
          "name": "Inhaled placebo @ 2 & 10 hours",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexza Pharmaceuticals, Inc.",
      "sponsor_class": "UNKNOWN",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 52,
      "start_date": "2009-05",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2017-03-15",
      "last_synced_at": "2026-10-02T15:24:39.893Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00890175"
    },
    {
      "nct_id": "NCT00874770",
      "title": "Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Infection"
      ],
      "interventions": [
        {
          "name": "Daclatasvir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon alpha-2a",
          "type": "DRUG"
        },
        {
          "name": "ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 74,
      "start_date": "2009-06",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2015-10-23",
      "last_synced_at": "2026-10-02T15:24:39.893Z",
      "location_count": 11,
      "location_summary": "Montgomery, Alabama • Aurora, Colorado • New Haven, Connecticut + 7 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Springfield",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00874770"
    },
    {
      "nct_id": "NCT00909766",
      "title": "Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "BMS-830216",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 113,
      "start_date": "2009-08",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2015-11-04",
      "last_synced_at": "2026-10-02T15:24:39.893Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00909766"
    },
    {
      "nct_id": "NCT02574637",
      "title": "Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Brazikumab IV Infusion",
          "type": "DRUG"
        },
        {
          "name": "Brazikumab SC Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 29,
      "start_date": "2016-01-05",
      "completion_date": "2018-01-29",
      "has_results": true,
      "last_update_posted_date": "2021-05-26",
      "last_synced_at": "2026-10-02T15:24:39.893Z",
      "location_count": 52,
      "location_summary": "Phoenix, Arizona • Lone Tree, Colorado • Clearwater, Florida + 25 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02574637"
    },
    {
      "nct_id": "NCT00004154",
      "title": "Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Fenretinide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "1998-07-30",
      "completion_date": "2005-03-01",
      "has_results": false,
      "last_update_posted_date": "2018-11-08",
      "last_synced_at": "2026-10-02T15:24:39.893Z",
      "location_count": 3,
      "location_summary": "Houston, Texas • Seattle, Washington",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004154"
    },
    {
      "nct_id": "NCT07766720",
      "title": "Effects of Eggshell Membrane and Curcumin Extract Supplementation, Separately or Combined, on Recovery From Intense Exercise",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Exercise-induced Muscle Soreness",
        "Exercise-induced Joint Pain",
        "Exercise-induced Joint Stiffness",
        "Exercise-induced Cartilage Turnover"
      ],
      "interventions": [
        {
          "name": "NEM® brand eggshell membrane powder",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "curQ+® brand highly absorbable curcumin",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "EM Placebo",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Curc Placebo",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "NEM® plus curQ+® combination",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "ESM Technologies, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "MALE",
        "summary": "18 Years to 40 Years · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2026-02-01",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-10-02T15:24:39.893Z",
      "location_count": 1,
      "location_summary": "College Station, Texas",
      "locations": [
        {
          "city": "College Station",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07766720"
    }
  ]
}